Synthetic Biologics Inc (SYN) Issues Earnings Results
Synthetic Biologics Inc (NYSEMKT:SYN) posted its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.03, Bloomberg Earnings reports.
Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.598 on Friday. The stock’s market cap is $72.89 million. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.90. The stock has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.64.
A number of research firms have issued reports on SYN. ValuEngine downgraded Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Friday, April 7th. Finally, William Blair reissued an “outperform” rating and set a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.46.
A number of institutional investors have recently bought and sold shares of SYN. Norges Bank acquired a new position in Synthetic Biologics during the fourth quarter valued at approximately $356,000. LMR Partners LLP acquired a new position in Synthetic Biologics during the second quarter valued at approximately $194,000. Creative Planning increased its position in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares during the last quarter. UBS Group AG increased its position in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the last quarter.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.